OLFML3 and colorectal carcinoma: These findings demonstrate that OLFML3 expression correlates with tumor-associated macrophage signatures in CRC patients and that anti-OLFML3 therapy impairs the recruitment of tumor-promoting TAMs to CRC tumors.